Survivorship care and patient follow-up, being pivotal to managing treatment plans for patients with breast cancer, were key topics of discussion at a recent Institute for Value-Based Medicine® event ...

COVID-19-related Medicare spending and health care use declined after acute infection, with minimal excess costs by weeks 13 to 40 after diagnosis.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Christina Poh confirmed that the disconnect between provider and patient experiences of shared decision-making resonates strongly with what she observes in clinical practice, noting that while care ...

Harrison noted that responses were observed across calreticulin mutation types and among patients with additional mutations, with minimal toxicity reported to date. She concluded by describing ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

ORIGIN 3 randomized 431 biopsy‑confirmed IgAN patients 1:1; atacicept 150 mg weekly SC produced the largest placebo‑adjusted UPCR reduction reported at week 36. Accelerated approval hinged on ...

Quest is the largest reference laboratory to embed oncology molecular ordering into OncoEMR MPI, with projected reach to 4,700 clinicians across ~1,600 community oncology sites. Integration targets ...

Confirmed Bundibugyo ebolavirus infections reached 1,708 with 580 deaths, increasing from early July counts and prompting WHO’s May 17 PHEIC designation. Unpaid wages and bonuses since mid-May ...

In a recent podcast, Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, offered a candid account ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...